MedTrace Logo

SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies

NCT03831295 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-11-22

No results posted yet for this study

Summary

This phase I trial studies the side effects of intratumoral injection of SD-101 and BMS-986178 in treating patients with solid malignancies that have spread to other places in the body. The TLR9 agonist SD-101 may stimulate the immune system in different ways and stop cancer cells from growing. BMS-986178 is a monoclonal anti-OX40 antibody that enhances the activation of T cells, immune cells that are important for fighting tumors. Giving TLR9 agonist SD-101 together with anti-OX40 antibody BMS-986178 may work better in treating patients with advanced solid tumors.

Conditions

  • Advanced Malignant Solid Neoplasm
  • Extracranial Solid Neoplasm
  • Metastatic Malignant Solid Neoplasm

Interventions

BIOLOGICAL

Anti-OX40 Antibody BMS 986178

Given IT or IV

DRUG

TLR9 Agonist SD-101

Given IT

Sponsors & Collaborators

Principal Investigators

  • Saad A Khan · Stanford Cancer Institute Palo Alto

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-13
Primary Completion
2021-10-04
Completion
2021-10-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03831295 on ClinicalTrials.gov